M. Helen Huls

Division of Pediatrics, U.T. MD Anderson Cancer Center

Affiliated withU.T. MD Anderson Cancer Center

Research Area

Biography

M. Helen Huls has not added Biography.
If you are M. Helen Huls and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title Cited by 53	2013
Publication title Cited by 22	2015

Other Publications

Article	Year
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 11777989	2002
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood\| PubMed ID: 11964281	2002
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood\| PubMed ID: 12393655	2002
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood\| PubMed ID: 12411306	2003
树突状细胞天生多克隆人类细胞毒 T 淋巴细胞行使用的&#x... Journal of immunotherapy (Hagerstown, Md. : 1997)\| PubMed ID: 12806278	2003
Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. Acta haematologica\| PubMed ID: 14583675	2003
A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer gene therapy\| PubMed ID: 14685154	2004
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood\| PubMed ID: 14751931	2004
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. Journal of immunotherapy (Hagerstown, Md. : 1997)\| PubMed ID: 15235393	2004
Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation\| PubMed ID: 15371682	2004
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood\| PubMed ID: 15542583	2005
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. The Journal of experimental medicine\| PubMed ID: 15611290	2004
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 16148164	2005
Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clinical lymphoma & myeloma\| PubMed ID: 16507214	2006
In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leukemia & lymphoma\| PubMed ID: 16753867	2006
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature medicine\| PubMed ID: 16998485	2006
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood\| PubMed ID: 17609424	2007
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood\| PubMed ID: 18971421	2009
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature medicine\| PubMed ID: 18978797	2008
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. Journal of immunotherapy (Hagerstown, Md. : 1997)\| PubMed ID: 20948438	2010
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. PloS one\| PubMed ID: 22279576	2012